Skip to main content
On Our Radar

Seven Molecules Identified as Potential Treatments for Familial Parkinson’s

By February 29, 2024No Comments

Seven Molecules Identified as Potential Treatments for Familial Parkinson’s

Conscience, a Canadian nonprofit biotech company, announced last month that seven molecules had been identified as potential treatments for familial Parkinson’s disease as a result of its CACHE Challenge. The Critical Assessment of Computational Hit-Finding Experiments (CACHE) Challenge takes a unique approach to drug discovery by combining artificial intelligence with an open-science, collaborative method not limited by patents or intellectual property.

The process began with a call to academic centers and commercial organizations to use AI and computational chemistry to identify molecules that would bind to the LRRK2 gene. This target was chosen because mutations on LRRK2 are the most common cause of inherited Parkinson’s disease. The Structural Genomics Consortium at the University of Toronto identified seven of 2,000 molecules at potential “hits,” and these results were validated by an independent review committee.

“In an era where new therapies for many diseases have been scarce despite substantial investment, the CACHE Challenge provides an alternative, collaborative model for drug development,” said Ryan Merkley, CEO of Conscience. “We can also celebrate the emergence of AI as a promising new tool for drug discovery.”

Additional CACHE Challenges are planned for Covid and a rare form of cancer. Data from the Parkinson’s CACHE Challenge are available to the public here.

Read the press release

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.